Health Canada has broadened the approval of Evkeeza® (evinacumab) to treat homozygous familial hypercholesterolemia (HoFH) in children as young as 6 months, offering exciting new hope for early and powerful treatment
Browsing: pediatric approval
Health Canada has broadened the approval of Evkeeza® (evinacumab) to treat homozygous familial hypercholesterolemia (HoFH) in children as young as 6 months, offering exciting new hope for early and powerful treatment